ArticleFrontiers in immunology2022

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.

Hui Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.